Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTXNASDAQ:ENTAOTCMKTS:MRMDOTCMKTS:PFSCF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$2.23-0.9%$1.67$1.20▼$6.75$126.80M2.631.51 million shs945,891 shsENTAEnanta Pharmaceuticals$5.97-3.1%$5.39$4.09▼$17.24$127.62M0.81284,709 shs176,864 shsMRMDMariMed$0.08-1.6%$0.09$0.07▼$0.29$32.50M3.15412,348 shs113,286 shsPFSCFProMetic Life Sciences$5.47$5.47$5.47▼$352.00$127.45M2.46279 shsN/AThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics0.00%+10.95%+25.28%+16.75%-53.35%ENTAEnanta Pharmaceuticals0.00%+2.75%+0.34%-18.55%-52.13%MRMDMariMed0.00%+12.97%-22.95%-24.00%-61.10%PFSCFProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDTXBlack Diamond Therapeutics3.4286 of 5 stars3.54.00.00.02.72.51.3ENTAEnanta Pharmaceuticals3.9167 of 5 stars3.41.00.04.73.52.50.0MRMDMariMed0.4589 of 5 stars0.03.00.00.01.50.80.6PFSCFProMetic Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 3.00Buy$14.60554.71% UpsideENTAEnanta Pharmaceuticals 2.80Moderate Buy$17.25188.94% UpsideMRMDMariMed 4.00Strong BuyN/AN/APFSCFProMetic Life Sciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MRMD, ENTA, PFSCF, and BDTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2025MRMDMariMedNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/19/2025BDTXBlack Diamond TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.003/18/2025BDTXBlack Diamond TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $12.003/7/2025BDTXBlack Diamond TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.003/7/2025BDTXBlack Diamond TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$16.00 ➝ $11.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond Therapeutics$70M1.81N/AN/A$2.26 per share0.99ENTAEnanta Pharmaceuticals$64.46M1.98N/AN/A$5.24 per share1.14MRMDMariMed$148.60M0.22$0.01 per share5.59$0.19 per share0.44PFSCFProMetic Life Sciences$36.55M3.49N/AN/A($67.63) per share-0.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics-$82.44M$0.06N/AN/AN/AN/A-68.08%-49.65%8/5/2025 (Estimated)ENTAEnanta Pharmaceuticals-$116.04M-$4.54N/AN/AN/A-157.57%-75.53%-27.30%8/11/2025 (Estimated)MRMDMariMed-$16.03M-$0.03N/A∞N/A-10.97%-2.75%-1.06%8/6/2025 (Estimated)PFSCFProMetic Life Sciences-$150.73MN/A0.00∞N/A-894.02%-3,350.55%-67.76%N/ALatest MRMD, ENTA, PFSCF, and BDTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q2 2025ENTAEnanta Pharmaceuticals-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million5/7/2025Q1 2025MRMDMariMed-$0.01-$0.01N/A-$0.01$38.33 million$37.96 million3/6/2025Q4 2024BDTXBlack Diamond Therapeutics-$0.31-$0.28+$0.03-$0.28N/AN/A3/5/2025Q4 2024MRMDMariMed-$0.01-$0.01N/A-$0.02$42.00 million$39.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AMRMDMariMedN/AN/AN/AN/AN/APFSCFProMetic Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A5.555.55ENTAEnanta PharmaceuticalsN/A5.475.47MRMDMariMed1.011.550.73PFSCFProMetic Life SciencesN/A0.950.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%ENTAEnanta Pharmaceuticals94.99%MRMDMariMed0.18%PFSCFProMetic Life Sciences0.10%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics8.87%ENTAEnanta Pharmaceuticals13.89%MRMDMariMed18.99%PFSCFProMetic Life SciencesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9056.86 million51.57 millionOptionableENTAEnanta Pharmaceuticals16021.38 million18.37 millionOptionableMRMDMariMed260388.71 million301.65 millionNot OptionablePFSCFProMetic Life Sciences5023.31 millionN/ANot OptionableMRMD, ENTA, PFSCF, and BDTX HeadlinesRecent News About These CompaniesPlant SciencesAugust 10, 2023 | uwyo.eduSocial SciencesJuly 29, 2023 | news.yale.eduOvercoming DNA Degradation in Forensic ScienceJune 7, 2023 | news-medical.netThe UK Life Sciences Real Estate Annual ConferenceFebruary 23, 2023 | bisnow.comNew 200-acre Life Sciences Development Proposed in PlanoFebruary 15, 2023 | dmagazine.comLife Sciences Keeps Boston as a Top 10 MarketJanuary 29, 2023 | globest.comThere's Been No Shortage Of Growth Recently For TMC Life Sciences Berhad's (KLSE:TMCLIFE) Returns On CapitalJanuary 29, 2023 | finance.yahoo.comIndia's Glenmark Life Sciences Q3 profit rises 1% on API strengthJanuary 29, 2023 | reuters.comUS Life Sciences Market Ends 2022 on Solid Ground: ReportJanuary 29, 2023 | commercialobserver.comOpportunities aplenty in the life sciences sectorJanuary 5, 2023 | irishtimes.comLife Sciences Funds Post Mixed Results in SeptemberOctober 16, 2022 | institutionalinvestor.comWhat Recession? Life Sciences Continues To BoomSeptember 24, 2022 | globest.comHere's what to expect from Prometic Life Sciences's earnings reportMay 10, 2022 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Undervalued Stocks Wall Street Is Getting WrongBy Gabriel Osorio-Mazilli | May 12, 2025View 3 Undervalued Stocks Wall Street Is Getting WrongSavvy Investors Are Raising a Glass for Heineken StockBy Chris Markoch | May 18, 2025View Savvy Investors Are Raising a Glass for Heineken StockIs It Time to Buy the Dip in Novo Nordisk Stock?By Chris Markoch | May 15, 2025View Is It Time to Buy the Dip in Novo Nordisk Stock?Is Reddit Stock a Buy, Sell, or Hold After Earnings Release?By Gabriel Osorio-Mazilli | May 5, 2025View Is Reddit Stock a Buy, Sell, or Hold After Earnings Release?Is NIO Stock Set for a Comeback? Fundamentals Say YesBy Gabriel Osorio-Mazilli | May 19, 2025View Is NIO Stock Set for a Comeback? Fundamentals Say YesMRMD, ENTA, PFSCF, and BDTX Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$2.23 -0.02 (-0.89%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$2.19 -0.04 (-1.97%) As of 08:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Enanta Pharmaceuticals NASDAQ:ENTA$5.97 -0.19 (-3.08%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$5.93 -0.04 (-0.67%) As of 07:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.MariMed OTCMKTS:MRMD$0.08 0.00 (-1.65%) As of 05/30/2025 03:18 PM EasternMariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.ProMetic Life Sciences OTCMKTS:PFSCF$5.47 0.00 (0.00%) As of 11/18/2019Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet Nike’s Amazon Expansion Could Signal a Turnaround in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
